Ernexa Therapeutics Inc. (ERNA) stock
ERNANasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ERNAW
$1.93−0.08 (-3.98%)
Close on Nov 11, 2026Market cap $3.15MP/E –Yield –
Ernexa Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Ernexa Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$14.56M. For fiscal 2025 it was -$9.25M. The highest annual figure on record is $2.97M in fiscal 2018.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$9.25M | – |
| FY2024 | Dec 31, 2024 | -$15.54M | – |
| FY2023 | Dec 31, 2023 | -$21.05M | – |
| FY2022 | Dec 31, 2022 | -$33.06M | – |
| FY2021 | Dec 31, 2021 | -$113.62M | – |
| FY2020 | Dec 31, 2020 | -$7.15M | – |
| FY2019 | Dec 31, 2019 | -$1.40M | -147.3% |
| FY2018 | Dec 31, 2018 | $2.97M | +224.3% |
| FY2017 | Dec 31, 2017 | $915.00K | +50.2% |
| FY2016 | Dec 31, 2016 | $609.00K | – |
| FY2015 | Dec 31, 2015 | -$3.79M | – |
| FY2014 | Dec 31, 2014 | -$2.00M | -215.4% |
| FY2013 | Dec 31, 2013 | $1.73M | -4.8% |
| FY2012 | Dec 31, 2012 | $1.82M | – |
| FY2011 | Dec 31, 2011 | -$16.00K | -100.6% |
| FY2010 | Dec 31, 2010 | $2.88M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$2.89M | – |
| Q2 FY2026 | Jun 30, 2026 | -$4.00M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.58M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.08M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.99M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.00M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.71M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.68M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.16M | – |
| Q2 FY2024 | Jun 30, 2024 | -$4.83M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.75M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.74M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.49M | – |
| Q2 FY2023 | Jun 30, 2023 | -$4.53M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.30M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.72M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.26M | – |
| Q2 FY2022 | Jun 30, 2022 | -$13.81M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.26M | – |
| Q4 FY2021 | Dec 31, 2021 | -$8.50M | – |
| Q3 FY2021 | Sep 30, 2021 | -$86.25M | – |
| Q2 FY2021 | Jun 30, 2021 | -$9.98M | – |
| Q1 FY2021 | Mar 31, 2021 | -$8.90M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.18M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.98M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.94M | -2331.3% |
| Q1 FY2020 | Mar 31, 2020 | -$991.54K | -287.1% |
| Q4 FY2019 | Dec 31, 2019 | -$1.14M | -231.2% |
| Q3 FY2019 | Sep 30, 2019 | -$228.00K | -151.2% |
| Q2 FY2019 | Jun 30, 2019 | $87.00K | +55.4% |
| Q1 FY2019 | Mar 31, 2019 | $530.00K | +62.6% |
| Q4 FY2018 | Dec 31, 2018 | $869.00K | +675.9% |
| Q3 FY2018 | Sep 30, 2018 | $445.00K | +1834.8% |
| Q2 FY2018 | Jun 30, 2018 | $56.00K | -6.7% |
| Q1 FY2018 | Mar 31, 2018 | $326.00K | – |
| Q4 FY2017 | Dec 31, 2017 | $112.00K | -71.7% |
| Q3 FY2017 | Sep 30, 2017 | $23.00K | – |
| Q2 FY2017 | Jun 30, 2017 | $60.00K | – |
| Q1 FY2017 | Mar 31, 2017 | -$255.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $396.00K | – |
See a number that looks wrong?